RPI’s David T. Corr Elected to AIMBE College of Fellows

David T. Corr, a professor of biomedical engineering at Rensselaer Polytechnic Institute, has been elected to The American Institute for Medical and Biological Engineering (AIMBE) College of Fellows class of 2023. 

The College of Fellows is among the most prestigious distinctions a biomedical engineer can achieve.  AIMBE is a nonprofit organization that represents “the most accomplished individuals in the fields of medical and biological engineering who are pioneering new and developing fields of technology, making major advancements in traditional fields of medical and biological engineering or developing/implementing innovative approaches to bioengineering education.”

Corr’s research aims to understand the impact of various microenvironmental and developmental stimuli on cell behavior, and to exploit these to improve functional tissue engineering and in vitro diagnostics. He and his lab have developed innovative experimental approaches to engineer functional musculoskeletal soft tissue fibers, and to fabricate 3D in vitro tumor models for drug testing and fundamental mechanistic studies.

He is a Fellow of the American Society of Mechanical Engineers (ASME), and Chair of Tissue and Cellular Engineering (TCE) Technical Committee of the Summer Biomechanics, Bioengineering, and Biotransport Conference.

David Corr Elected Fellow of ASME

David Corr, an associate professor of biomedical engineering at Rensselaer Polytechnic Institute, has been elected as a fellow of the American Society of Mechanical Engineers (ASME).

The distinction of fellow recognizes ASME members who have contributed significant engineering achievements. Corr joins a distinct group of less than 3,500 fellows among nearly 90,000 ASME members.

Corr’s research specializes in soft tissue biomechanics, laser-based biofabrication techniques to create cellular microenvironments, and developing cell-based strategies to engineer musculoskeletal soft tissue replacements. His group investigates the impact of various biophysical stimuli on cell behavior and fate decisions, and seeks to use this to improve functional soft tissue engineering. His lab pioneered a bioprinting method to create spatially-precise cellular cultures and constructs, which is now being used to engineer tissue models for applications in cancer and in vitro diagnostics. His group is also researching ways to improve tissue-engineered tendon and skeletal muscle through the use of an embryonic-inspired scaffold-free approach to tissue generation.

He is a member of several other professional societies, including the Orthopaedic Research Society and Biomedical Engineering Society. Corr has held memberships in the American Physiological Society, the American Society of Biomechanics, the Canadian Society for Biomechanics, and the Wound Healing Society. Corr is a member of the International Advisory Committee, and has served as the scientific program chair and conference chair for the International Symposium on Ligaments and Tendons. Within ASME’s Bioengineering Division, Corr is a two-term associate editor of the ASME Journal of Biomechanical Engineering, and he is a member of the technical committee on Biosolids and Tissue, as well as the Cellular Engineering technical committee.

Targeting Cancer Drugs to 3D-Printed Tumors

Targeting Cancer Drugs to 3D-Printed Tumors

The Corr lab at RPI and their collaborators at Albany Medical Center were featured by the American Society of Mechanical Engineering for their work in developing 3D bioprinting and imaging techniques designed to generate and analyze tumor models outside the body.... “To achieve that, we have to not only develop new 3D bioprinting techniques to generate tumor models with prescribed cell composition and architecture, but also new imaging techniques to visualize how different drugs interact with cancer cells depending on where they are located within these tumor models.”

Researchers awarded $3.7M Grant: Advancing Personalized Anti-Cancer Drugs

Researchers at Rensselaer Polytechnic Institute and Albany Medical Center are working together to develop three-dimensional bioprinting and imaging techniques that will generate and analyze tumor models in the laboratory, with the goal of accelerating the development and optimization of personalized anti-cancer drugs.

Hacking Healthcare and Helping Cancer Patients

Michael Bramson, a 1st year PhD student in the Corr lab, was on one of three winning teams at the 2nd annual Mount Sinai Health Hackathon, and his team was awarded $2500 for their innovative platform Streamline, a web-based service designed to use natural language processing in assisting researchers write clinical trial applications and protocols

Stem Cell Research Projects Displayed

Preliminary results of stem cell research projects sponsored by the Center for Biotechnology and Interdisciplinary Studies (CBIS) were displayed during a poster session and researcher networking lunch held December 2, in the CBIS auditorium and the Senator William H. Hernstadt ’57 and Jerene Yap Hernstadt Gallery.